SubsidieMeestersClosed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation
Celeris Therapeutics leverages deep learning to develop a web platform for degrading undruggable proteins, aiming to revolutionize drug discovery for incurable diseases like Alzheimer's and cancer.
Projectdetails
Introduction
Celeris Therapeutics is a deep learning company that uses innovative, in-silico methods such as geometric deep learning and graph neural networks to degrade currently undruggable targets (pathogenic proteins). The platform shall make a broad impact by addressing currently incurable diseases such as Alzheimer's, Parkinson's, and different types of cancer like breast and prostate cancer.
Technical Solution
Celeris Therapeutics' technical solution is the web application (orchestration platform) Celeris One.
Modules
It consists of three modules:
- Hades - target ID
- Xanthos - predicting biomolecular interactions and ligand design
- Hephaistos - automated synthesis and validation
Market Focus
The addressed market is in the early-stage drug discovery, and users are pharmaceutical and biotech companies with a focus on Targeted Protein Degradation.
Target Customers
The targeted customers are medicinal and computational chemists, who currently rely on docking, which is computationally intensive, slow, and inaccurate compared to CelerisTx deep learning methods.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.860.501 |
Tijdlijn
| Startdatum | 1-7-2022 |
| Einddatum | 29-2-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CELERIS THERAPEUTICS GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The ProM platform: New ways to drug the undruggablePROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer. | EIC Accelerator | € 2.461.375 | 2022 | Details |
Next generation HPC/QC in silico drug discovery platform for de novo designATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Multi-omic data driven drug discovery and indication prioritisation platform in oncologymCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies. | EIC Accelerator | € 2.495.788 | 2022 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
The ProM platform: New ways to drug the undruggable
PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.
Next generation HPC/QC in silico drug discovery platform for de novo design
ATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027.
Multi-omic data driven drug discovery and indication prioritisation platform in oncology
mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Learning and modeling the molecular response of single cells to drug perturbationsDeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings. | ERC Advanced... | € 2.497.298 | 2023 | Details |
Cloudplatform for High Content ImagingCore Life Analytics ontwikkelt een cloudplatform voor onafhankelijke onderzoekers om snel en kosteneffectief HC data-analyse uit te voeren. | Mkb-innovati... | € 20.000 | 2023 | Details |
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approachTrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space. | ERC Starting... | € 1.499.625 | 2022 | Details |
GOLGITACs: Targeted Degradation of Golgi Apparatus residing Carbohydrate Processing EnzymesSWEET DEGRADATION aims to develop GolgiTACs for targeted protein degradation of carbohydrate processing enzymes, offering new therapeutic strategies for glycan-related diseases. | ERC Starting... | € 1.500.000 | 2025 | Details |
Genetically anchored drug target discovery for neglected diseasesGenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases. | ERC Starting... | € 1.498.089 | 2024 | Details |
Learning and modeling the molecular response of single cells to drug perturbations
DeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings.
Cloudplatform for High Content Imaging
Core Life Analytics ontwikkelt een cloudplatform voor onafhankelijke onderzoekers om snel en kosteneffectief HC data-analyse uit te voeren.
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach
TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.
GOLGITACs: Targeted Degradation of Golgi Apparatus residing Carbohydrate Processing Enzymes
SWEET DEGRADATION aims to develop GolgiTACs for targeted protein degradation of carbohydrate processing enzymes, offering new therapeutic strategies for glycan-related diseases.
Genetically anchored drug target discovery for neglected diseases
GenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases.